Kestra Medical Technologies Debuts Cardiac Recovery System at 2025 HFSA Annual Scientific Meeting

Kestra Medical Technologies will showcase its Cardiac Recovery System at the HFSA Annual Scientific Meeting, focusing on heart failure recovery.

Quiver AI Summary

Kestra Medical Technologies, Ltd. announced their participation in the 2025 Heart Failure Society of America Annual Scientific Meeting in Minneapolis, showcasing their Cardiac Recovery System® (CRS) platform, which includes the ASSURE® Wearable Cardioverter Defibrillator. The CRS platform aims to enhance protection against sudden cardiac death while providing valuable insights for caregivers during the critical early recovery phase of heart failure patients. Attendees can explore the platform through interactive demonstrations that emphasize its role in improving patient-caregiver relationships and recovery processes. CEO Brian Webster highlighted the company's commitment to advancing heart failure care and improving patient outcomes through innovative technologies. Kestra will also present at the Devices in Heart Failure Meeting, focusing on the integration of the ASSURE system into clinical practices.

Potential Positives

Kestra Medical Technologies is debuting its Cardiac Recovery System® at a major industry event, which enhances visibility and brand recognition in the healthcare sector.
The CRS platform addresses a critical need in heart failure care, potentially leading to improved patient outcomes and attracting interest from healthcare professionals.
The immersive booth experience and hands-on demonstrations are likely to engage attendees effectively and foster direct connections with clinicians and providers.
The participation in the Devices in Heart Failure Meeting indicates a proactive approach to educating the industry on the integration of their technologies into existing medical practices.

Potential Negatives

None

FAQ

What is the purpose of Kestra's presence at the HFSA Annual Scientific Meeting?

Kestra aims to showcase its Cardiac Recovery System® and demonstrate its commitment to advancing heart failure care.

What does the Cardiac Recovery System® (CRS) platform do?

The CRS platform integrates protection with actionable insights for managing sudden cardiac death risk during heart failure recovery.

Where can attendees find Kestra at the HFSA meeting?

Attendees can visit Kestra at booth #920 during the HFSA Annual Scientific Meeting in Minneapolis.

What technology will be featured at Kestra's booth?

Kestra will feature the ASSURE® Wearable Cardioverter Defibrillator as part of its Cardiac Recovery System platform.

How does Kestra support clinicians and patients?

Kestra empowers clinicians with technology and insights that strengthen patient-provider connections and support recovery for heart failure patients.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$KMTS Analyst Ratings

Wall Street analysts have issued reports on $KMTS in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Wells Fargo issued a "Overweight" rating on 07/17/2025
Wolfe Research issued a "Outperform" rating on 03/31/2025
Stifel issued a "Buy" rating on 03/31/2025
Piper Sandler issued a "Overweight" rating on 03/31/2025

To track analyst ratings and price targets for $KMTS, check out Quiver Quantitative's $KMTS forecast page.

$KMTS Price Targets

Multiple analysts have issued price targets for $KMTS recently. We have seen 5 analysts offer price targets for $KMTS in the last 6 months, with a median target of $27.0.

Here are some recent targets:

Larry Biegelsen from Wells Fargo set a target price of $27.0 on 07/17/2025
David Roman from Goldman Sachs set a target price of $23.0 on 04/16/2025
Mike Polark from Wolfe Research set a target price of $29.0 on 03/31/2025
Rick Wise from Stifel set a target price of $28.0 on 03/31/2025
Matt O'Brien from Piper Sandler set a target price of $27.0 on 03/31/2025

Full Release

KIRKLAND, Wash., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced its debut at the 2025 Heart Failure Society of America (HFSA) Annual Scientific Meeting, September 26–29 in Minneapolis, Minnesota.

At booth #920, Kestra will feature its Cardiac Recovery System ^® (CRS) platform, anchored by the ASSURE ^® Wearable Cardioverter Defibrillator. The CRS platform closes the critical gap in sudden cardiac death protection by pairing protection with actionable insights that support confident care during the high-risk early phase of heart failure recovery.

Attendees can explore the CRS platform through an immersive booth experience and hands-on demonstrations that highlight how it empowers clinicians, strengthens patient–provider connections, and supports recovery for vulnerable patients.

“Our presence at HFSA underscores Kestra’s commitment to advancing care for heart failure patients,” said Brian Webster, President and Chief Executive Officer of Kestra Medical Technologies. “The Cardiac Recovery System platform redefines how sudden cardiac arrest risk is managed, equipping clinicians with technologies and insights that protect patients and strengthen recovery support.”

Kestra will also participate in the Devices in Heart Failure Meeting on Friday, September 26, where attendees can see the ASSURE system up close and learn how it integrates into clinical workflows to support guideline-directed medical therapy.

About Kestra
Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, please visit www.kestramedical.com .